Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 50, Pages 20200-20205
Publisher
Proceedings of the National Academy of Sciences
Online
2013-11-27
DOI
10.1073/pnas.1313654110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Magnitude of Thymic Output Is Genetically Determined through Controlled Intrathymic Precursor T Cell Proliferation
- (2014) G. Dulude et al. JOURNAL OF IMMUNOLOGY
- Homeostasis of the Naive CD4+ T Cell Compartment during Aging
- (2014) R. D. Kilpatrick et al. JOURNAL OF IMMUNOLOGY
- Homeostatic Proliferation of Lymphocytes Results in Augmented Memory-Like Function and Accelerated Allograft Rejection
- (2014) V. F. Moxham et al. JOURNAL OF IMMUNOLOGY
- Maintenance of Peripheral Naive T Cells Is Sustained by Thymus Output in Mice but Not Humans
- (2012) Ineke den Braber et al. IMMUNITY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease
- (2011) Marius Strioga et al. IMMUNOLOGY
- Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
- (2011) Grant A Hill-Cawthorne et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Helios Expression Is a Marker of T Cell Activation and Proliferation
- (2011) Tatiana Akimova et al. PLoS One
- T Cell Receptor-Dependent Regulation of Lipid Rafts Controls Naive CD8+ T Cell Homeostasis
- (2010) Jae-Ho Cho et al. IMMUNITY
- Cutting Edge: Programmed Death-1 Defines CD8+CD122+ T Cells as Regulatory versus Memory T Cells
- (2010) H. Dai et al. JOURNAL OF IMMUNOLOGY
- Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cells
- (2010) A. M. Thornton et al. JOURNAL OF IMMUNOLOGY
- Comprehensive assessment of T-cell receptor -chain diversity in T cells
- (2009) H. S. Robins et al. BLOOD
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells
- (2009) Martin Guimond et al. NATURE IMMUNOLOGY
- CD4+CD25+FOXP3+Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H
- (2008) D. D. Bloom et al. AMERICAN JOURNAL OF TRANSPLANTATION
- IL-7 sustains CD31 expression in human naive CD4+ T cells and preferentially expands the CD31+ subset in a PI3K-dependent manner
- (2008) R. I. Azevedo et al. BLOOD
- Association of Graves’ Disease and Prevalence of Circulating IFN-γ-producing CD28− T Cells
- (2008) Zhiping Sun et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions
- (2008) C. Le Saout et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started